Blocking macrophage scavenger receptor 1 (MSR1) in vitro reduced saturated fatty acid-induced inflammatory gene expression in primary MFs and in vivo administration of an anti-MSR1 antibody ameliorated liver inflammation in a NAFLD mouse model [155,180]. Here, MSR1 is linked to metabolic dysfunction-associated steatotic liver disease.